Mayo cardiologists say the quickest fix is often the least durable one
Patients still walk into clinic hoping for a shortcut. They want a number to drop, a pill to do the work, or a single intervention that seems to erase years of cardiovascular risk in one visit. In a recent conversation, two preventive cardiologists from Mayo Clinic argued for a different clinical path: help patients move from inaction to action, even when the first change feels modest. The practical target is not perfection. It is momentum.
Francisco Lopez-Jimenez, M.D., M.S., and Kyla M. Lara-Breitinger, M.D., M.S., both of Mayo Clinic, framed heart prevention as a long game built on behavior patients can actually control. Their advice was not abstract. It centered on the realities of primary care visits, where time is short, risk is layered, and patients often arrive expecting a prescription rather than a conversation. Lopez-Jimenez pointed to a useful bedside question for patients who do not own a blood pressure cuff: how many televisions do you have? The point is simple. If home monitoring is unrealistic in one setting, clinicians need another practical way to understand the home environment and the patient’s access to self-monitoring.
One sentence captures the entire problem: patients often want a quick fix for a chronic disease process that did not develop quickly.
Behavior beats the obsession with a single target
The guests pushed hard against the instinct to focus only on one lab value or one blood pressure reading. A blood pressure number matters, but patients do better when the goal is a behavior they can influence today, such as eating less salt. That approach shifts the discussion from a metric the patient may not directly control to a habit they can repeat in the kitchen, at the grocery store, or at a restaurant table. It also reduces the sense of failure that can come from chasing an isolated reading without changing the daily pattern behind it.
Lara-Breitinger described delayed gratification as one reason cardiovascular prevention is such a hard sell. Patients are asked to make small sacrifices now for benefits that may not feel immediate. In practice, that means primary care physicians often need to translate long-term vascular biology into short-term goals that feel real. Less salt, more movement, improved sleep, and attention to stress may not sound dramatic, but these changes are the ones patients can sustain. The clinical task is to identify the one change a person is ready to make and build from there.
Risk assessment has to reach beyond BMI and the standard lipid panel
The conversation also moved into risk stratification, where traditional markers do not always tell the whole story. Lara-Breitinger discussed normal weight obesity and the limits of body mass index, a reminder that a normal BMI does not guarantee low cardiometabolic risk. Where body fat is carried can matter more than the number on the scale. Central adiposity, visceral fat, and other patterns of fat distribution can signal a higher-risk phenotype even when the patient looks “normal weight” by standard screening language.
That clinical nuance has consequences at the bedside. A patient with a seemingly acceptable BMI may still have an unfavorable metabolic profile, while another patient with a higher BMI may be metabolically healthier than expected. Waist circumference can help, but it is not always easy to measure in a 15- to 30-minute appointment, especially when the workflow is already crowded. Still, the message is hard to ignore: body habitus should not be reduced to one number on the intake sheet.
Advanced lipid markers were part of the discussion as well. Lara-Breitinger cited high-sensitivity C-reactive protein, lipoprotein(a), and apolipoprotein B as tools that can deepen cardiovascular risk assessment beyond a standard lipid panel. These tests can help identify residual risk and clarify why two patients with similar basic cholesterol values may not carry the same level of threat. The biological rationale is straightforward. Inflammation, inherited lipoprotein burden, and the total number of atherogenic particles all contribute to vascular injury in ways that a basic panel can miss.
Home blood pressure readings need to matter inside the EHR
Blood pressure management became a major theme because the home reading is often more revealing than the office measurement. Lopez-Jimenez emphasized getting home blood pressure data into the electronic health record without burying clinicians in extra work. That is an implementation problem with direct clinical consequences. If home readings are accurate but inaccessible, the data are wasted. If they are entered in a way that overwhelms the physician, the system fails in a different direction.
Not every device is reliable, and not every patient has equal access to a validated cuff. Even so, diagnosis should happen at home when possible, because office readings can be distorted by stress, timing, or the encounter itself. Lara-Breitinger stressed that patients need to hear that blood pressure is a big deal. They also need to understand why a home number, repeated over time, can be more meaningful than a single office snapshot. In cardiovascular prevention, repeated exposure matters. Arterial injury accumulates quietly, and sustained elevation is far more important than a one-time spike.
GLP-1 prescribing without specialist backup requires sharper judgment
The conversation turned more cautious when GLP-1 drugs entered the discussion. Lara-Breitinger described the patients who clearly qualify, but also the difficult edge cases, such as a person with a BMI of 25 or 26. Those patients do not fit neatly into binary rules, and cost can become the deciding factor when someone is paying full price out of pocket. The clinical question is not whether these agents can be effective. The question is whether they are the right tool, at the right time, for the right patient, especially when specialist support is not available.
Primary care clinicians are often left to make those calls first. The risk is not only financial. Inappropriate prescribing can crowd out the slower work of lifestyle change, and some patients may interpret medication as a substitute for habits that still need attention. The more durable strategy is to define candidacy carefully, explain the limits of the drug, and keep the emphasis on cardiovascular risk reduction rather than weight loss alone.
Prevention works best when the patient owns one change
Lopez-Jimenez’s prevention framework centered on four tenets, while Lara-Breitinger returned to a deceptively simple question: what brings the patient joy? That question can surface a usable target for behavior change. A person who walks to decompress, cooks for family, or values time outside may be more likely to keep a plan if the plan is tied to something meaningful rather than punitive. The same principle applies to cholesterol management, where lowering low-density lipoprotein cholesterol remains a core goal, but one that is easier to sustain when it is linked to the patient’s own priorities.
This is where prevention becomes clinically believable. Patients do not need a perfect program on day one. They need a reason to start, a way to track progress, and a clinician willing to make the next step feel manageable. The Mayo cardiologists’ message was unambiguous: the best cardiovascular intervention may be the one the patient can actually do tomorrow.
The unanswered practical question is how many primary care workflows can absorb these conversations without sacrificing time for everything else already packed into the visit.